首页> 外文期刊>Journal of drug targeting >A new pressure-controlled colon delivery capsule for chronotherapeutic treatment of nocturnal asthma.
【24h】

A new pressure-controlled colon delivery capsule for chronotherapeutic treatment of nocturnal asthma.

机译:一种新型压力控制结肠递送胶囊,用于夜间哮喘的计时治疗。

获取原文
获取原文并翻译 | 示例
           

摘要

The purpose of this study was to prepare a pressure-controlled colon delivery capsule (PCDC) containing theophylline (TPH) dispersion in a lipid matrix as a chronotherapeutic drug delivery system for the treatment of nocturnal asthma. The system was made by film coating using Eudragit S100- based formula over the sealed-hard gelatin capsules containing the drug-lipid dispersion. The lipid formula was composed mainly of Gelucire 33/01 (G33) with different ratios of surfactants (1-10%). The efficiency of the prepared system was evaluated in vitro for its ability to withstand both the gastric and intestinal medium. In addition, the drug plasma concentrations were monitored after single administration to Beagle dogs and compared to that obtained after administration of a reference marketed, generic, sustained-release TPH tablets, Avolen((R)) SR. It was found that the optimum lipid formula was GL2 containing 90% G33 and 10% Labrasol. The film-coated capsules showed complete resistance to both the acidic environment (pH 1.2) for 2 hours and phosphate buffer pH 6.8 for 3 hours at 37 degrees C. In vivo evaluation of the TPH-based PCDCs showed longer lag time compared TO the marketed formula followed by sudden increase in TPH blood levels, which recommends the high potential of this system as a chronotherapeutic drug delivery for nocturnal asthma. The prepared PCDCs exhibited a significantly higher C(max) and T(max) and a nonsignificantly different AUC compared with Avolen((R)) SR. Higher TPH blood levels from 1 to 8 hours postadministration was detected in the case of the prepared PCDCs.
机译:这项研究的目的是制备一种压力控制的结肠输送胶囊(PCDC),该胶囊在脂质基质中包含茶碱(TPH)分散体,作为用于治疗夜间哮喘的计时药物输送系统。该系统通过在包含药物-脂质分散体的密封硬明胶胶囊上使用基于Eudragit S100的配方进行薄膜包衣制成。脂质配方主要由Gelucire 33/01(G33)和不同比例的表面活性剂(1-10%)组成。在体外评估了所制备系统的耐受胃和肠介质的能力。另外,在单剂量给予Beagle犬后监测药物血浆浓度,并将其与给予参考市售的通用缓释TPH片剂Avolen(R)SR后的血浆浓度进行比较。发现最佳脂质配方是含有90%G33和10%Labrasol的GL2。薄膜包衣的胶囊在37摄氏度下对酸性环境(pH 1.2)持续2小时和对磷酸盐缓冲液pH 6.8持续3小时均具有完全的抵抗力。与市场上出售的相比,基于TPH的PCDC的体内评估显示出更长的延迟时间配方,随后TPH血药浓度突然升高,这建议该系统具有潜力,可以作为夜间哮喘的计时治疗药物。与SR相比,制备的PCDC表现出明显更高的C(max)和T(max)以及无显着差异的AUC。对于准备好的PCDC,从给药后1至8小时检测到较高的TPH血液水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号